MedAssets (Nasdaq: MDAS) reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), MedAssets beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share grew. GAAP earnings per share grew significantly.

Gross margins dropped, operating margins increased, net margins grew.

Revenue details
 MedAssets chalked up revenue of $170.7 million. The 15 analysts polled by S&P Capital IQ foresaw a top line of $167.8 million on the same basis. GAAP reported sales were 4.7% higher than the prior-year quarter's $163.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.30. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.26 per share. Non-GAAP EPS of $0.30 for Q2 were 7.1% higher than the prior-year quarter's $0.28 per share. GAAP EPS of $0.08 for Q2 were 100% higher than the prior-year quarter's $0.04 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 78.0%, 70 basis points worse than the prior-year quarter. Operating margin was 12.8%, 50 basis points better than the prior-year quarter. Net margin was 3.0%, 160 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $167.1 million. On the bottom line, the average EPS estimate is $0.30.

Next year's average estimate for revenue is $679.0 million. The average EPS estimate is $1.29.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 66 members out of 80 rating the stock outperform, and 14 members rating it underperform. Among 31 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give MedAssets a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $21.42.

Is MedAssets the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.